6452-73-9 Usage
Description
Oxprenolol hydrochloride is a non-selective β-adrenergic receptor (β-AR) antagonist that exhibits high affinity for both β1and β2-ARs. It is an orally bioavailable compound with a Ki value of 7.10 nM in a radioligand binding assay using rat heart tissue. Oxprenolol hydrochloride is selective for β-ARs over serotonin (5-HT) receptors in rat sarcolemmal membrane preparations, but it also binds to 5-HT1A receptors in rat hippocampus and 5-HT1B in rat striatum. Formulations containing oxprenolol hydrochloride have been utilized for the treatment of hypertension and angina pectoris.
Uses
Used in Pharmaceutical Industry:
Oxprenolol hydrochloride is used as an antihypertensive agent for the treatment of hypertension. It helps in lowering blood pressure by blocking the effects of adrenaline on β-ARs, thereby reducing heart rate and the force of heart contractions.
Oxprenolol hydrochloride is also used as an adrenergic receptor antagonist for the management of angina pectoris. It works by reducing the workload on the heart, which in turn alleviates chest pain and improves blood flow to the heart muscle.
Therapeutic Function
Antiarrhythmic
Biological Activity
Non-selective β -adrenergic antagonist.
Clinical Use
Beta-1 adrenoceptor blocker:
Hypertension
Angina
Arrhythmias
Anxiety
Drug interactions
Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Analgesics: NSAIDs antagonise hypotensive effect.
Anti-arrhythmics: increased risk of myocardial
depression and bradycardia; increased risk of
bradycardia, myocardial depression and AV block
with amiodarone; increased risk of myocardial
depression and bradycardia with flecainide.
Antidepressants: enhanced hypotensive effect with
MAOIs.
Antihypertensives: enhanced hypotensive effect;
increased risk of first dose hypotensive effect with
post-synaptic alpha-blockers such as prazosin;
increased risk of withdrawal hypertension with
clonidine; increased risk of bradycardia and AV
block with diltiazem; severe hypotension and heart
failure occasionally with nifedipine; asystole, severe
hypotension and heart failure with verapamil.
Antimalarials: increased risk of bradycardia with
mefloquine.
Antipsychotics: enhanced hypotensive effect with
phenothiazines.
Cytotoxics: possible increased risk of bradycardia
with crizotinib.
Diuretics: enhanced hypotensive effect.
Fingolimod: possibly increased risk of bradycardia.
Moxisylyte: possibly severe postural hypotension.
Sympathomimetics: severe hypertension with
adrenaline and noradrenaline (especially with nonselective beta-blockers) and possibly with dopamine.
Metabolism
Oxprenolol is extensively metabolised in the liver, direct
O-glucuronidation being the major metabolic pathway
and oxidative reactions minor ones. Oxprenolol is
excreted chiefly in the urine (almost exclusively in the
form of inactive metabolites).
Check Digit Verification of cas no
The CAS Registry Mumber 6452-73-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,4,5 and 2 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 6452-73:
(6*6)+(5*4)+(4*5)+(3*2)+(2*7)+(1*3)=99
99 % 10 = 9
So 6452-73-9 is a valid CAS Registry Number.
InChI:InChI=1/C15H23NO3.ClH/c1-4-9-18-14-7-5-6-8-15(14)19-11-13(17)10-16-12(2)3;/h4-8,12-13,16-17H,1,9-11H2,2-3H3;1H
